About Re-Vana Therapeutics
Re-Vana Therapeutics is a company based in Belfast (United Kingdom) founded in 2015.. Re-Vana Therapeutics has raised $16.75 million across 4 funding rounds from investors including Visionary Ventures, ExSight Ventures and InFocus Capital Partners. Re-Vana Therapeutics offers products and services including EyeLief, EyeLief-SD, and OcuLief. Re-Vana Therapeutics operates in a competitive market with competitors including Eyenovia, iVeena Delivery Systems, Kedalion Thera, PolyActiva and On Demand Therapeutics, among others.
- Headquarter Belfast, United Kingdom
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Re-Vana Therapeutics Ltd
- Date of Incorporation 09 May, 2016
- Jurisdiction BELFAST, NORTHERN IRELAND
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$16.75 M (USD)
in 4 rounds
-
Latest Funding Round
$11.9 M (USD), Series A
Nov 30, 2022
-
Investors
Visionary Ventures
& 6 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Re-Vana Therapeutics
Re-Vana Therapeutics offers a comprehensive portfolio of products and services, including EyeLief, EyeLief-SD, and OcuLief. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Pre-formed biodegradable implant for up to six months of drug release.
Variant implant for elevated drug release rates in ocular treatments.
In-situ forming gel for sustained drug delivery in the eye.
Unlock access to complete
Unlock access to complete
Funding Insights of Re-Vana Therapeutics
Re-Vana Therapeutics has successfully raised a total of $16.75M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $11.9 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series A — $11.9M
-
First Round
First Round
(01 Jun 2017)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2022 | Amount | Series A - Re-Vana Therapeutics | Valuation | Visionary Ventures | |
| Jun, 2020 | Amount | Seed - Re-Vana Therapeutics | Valuation | Visionary Ventures |
|
| Jun, 2020 | Amount | Seed - Re-Vana Therapeutics | Valuation | Exsight Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Re-Vana Therapeutics
Re-Vana Therapeutics has secured backing from 7 investors, including venture fund investors. Prominent investors backing the company include Visionary Ventures, ExSight Ventures and InFocus Capital Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A venture capital fund focused on life sciences investments.
|
Founded Year | Domain | Location | |
|
ExSight Ventures is focused on early-stage ophthalmic investments.
|
Founded Year | Domain | Location | |
|
Investment opportunities in ophthalmic innovations are managed by InFocus.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Re-Vana Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Re-Vana Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Re-Vana Therapeutics Comparisons
Competitors of Re-Vana Therapeutics
Re-Vana Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Eyenovia, iVeena Delivery Systems, Kedalion Thera, PolyActiva and On Demand Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Microdose therapies for myopia treatment are developed with Optejet dispenser.
|
|
| domain | founded_year | HQ Location |
Ocular drug products for drop-free cataract surgery are developed.
|
|
| domain | founded_year | HQ Location |
Provider of drug delivery system for eye diseases
|
|
| domain | founded_year | HQ Location |
A platform for slow-release, site-specific drug delivery is developed.
|
|
| domain | founded_year | HQ Location |
Develops laser-activated implants for targeted drug delivery.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Re-Vana Therapeutics
Frequently Asked Questions about Re-Vana Therapeutics
When was Re-Vana Therapeutics founded?
Re-Vana Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is Re-Vana Therapeutics located?
Re-Vana Therapeutics is headquartered in Belfast, United Kingdom. It is registered at Belfast, Northern Ireland, United Kingdom.
Who is the current CEO of Re-Vana Therapeutics?
Michael O’Rourke is the current CEO of Re-Vana Therapeutics.
Is Re-Vana Therapeutics a funded company?
Re-Vana Therapeutics is a funded company, having raised a total of $16.75M across 4 funding rounds to date. The company's 1st funding round was a Seed of $2.08M, raised on Jun 01, 2017.
What does Re-Vana Therapeutics do?
Re-Vana Therapeutics was founded in 2015 in Belfast, United Kingdom, where a drug delivery platform for ophthalmic diseases is developed. Chronic eye conditions, including age-related macular degeneration, diabetic retinopathy, and glaucoma, are addressed by the platform. The flagship product, EyeLief, is provided as a photo cross-linked sustained-release biodegradable implant capable of delivering both biologic and small molecule drugs.
Who are the top competitors of Re-Vana Therapeutics?
Re-Vana Therapeutics's top competitors include Eyenovia, PolyActiva and iVeena Delivery Systems.
What products or services does Re-Vana Therapeutics offer?
Re-Vana Therapeutics offers EyeLief, EyeLief-SD, and OcuLief.
Who are Re-Vana Therapeutics's investors?
Re-Vana Therapeutics has 7 investors. Key investors include Visionary Ventures, ExSight Ventures, InFocus Capital Partners, Qubis, and Co-Fund NI.